Physician profile
Patrick C Ma
NPI 1104846823
$42,094.90
in general payments reported to CMS, 2019-2025
20 companies · $90.93 in 2025
The $90.93 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2021: $8,930 · 2022: $7,878 · 2023: $2,677 · 2024: $4,629 · 2025: $90.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,683 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,440 · Food and Beverage: $245 · Education: $29.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,682.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,440.00 |
| Food and Beverage | $244.93 |
| Education | $29.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $20,887.97 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $7,277.98 | 2019 | |
| Daiichi Sankyo INC. | $3,082.50 | 2024 | |
| Beigene USA, INC. | $2,600.00 | 2023 | |
| Astrazeneca Uk Limited | $2,397.50 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $1,625.00 | 2021 | |
| Janssen Global Services, LLC | $1,500.00 | 2021 | |
| Pfizer INC. | $1,452.00 | 2024 | |
| Janssen Scientific Affairs, LLC | $1,010.00 | 2021 | |
| Caris Mpi, INC. | $90.93 | 2025 | Mi Cancer Seek |
| Genentech USA, INC. | $77.03 | 2024 | |
| Incyte Corporation | $76.97 | 2023 | Pemazyre, Monjuvi, Jakafi |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.